The Philippines' **Asian Hospital and Medical Centre** has achieved remarkable recognition at the **Asian Management Excellence Awards 2026**, securing two distinguished titles: **Philippines Innovator of the Year - Healthcare** and **Philippines Team of the Year - Healthcare**. These awards celebrate the outstanding performance of its **Asian Cancer Institute (ACI)**, which has exceeded organizational targets through enhanced operational efficiency, superior patient experiences, and groundbreaking clinical innovations, particularly the introduction of the **CyberKnife S7** system.[1]

In the fiscal period of 2024-2025, ACI generated **PHP363.8 million in revenue**, surpassing its ambitious 30.2% growth target by achieving a 41% year-to-date increase as of September 2025. This success stems from a meticulously coordinated, team-based approach that prioritizes patient-centered, holistic cancer care. ACI operates through six specialized, interdisciplinary centers that form an integrated continuum of care: Breast, Simply Women, Emmanuel, Chrys 1 Infusion, Conquer C, and Chrys 2 Supportive and Integrative Care. These centers collectively address every phase of the cancer journey, from prevention and early diagnosis to advanced treatment, survivorship support, and compassionate end-of-life care.[1]

Facing significant operational pressures, the ACI team implemented a series of strategic solutions to maintain service excellence. These included active patient navigation programs, extended operating hours to accommodate more patients, expansion of the infusion unit with reduced turnaround times, seamless interdisciplinary integration of CyberKnife technology, bolstered manpower resources, and comprehensive supportive care services. To promote equitable access to care, ACI expanded its PhilHealth-aligned packages, introduced flexible chemotherapy brand options, and enhanced innovative drug assistance programs, ensuring that financial barriers do not impede quality treatment.[1]

Infrastructure upgrades have further elevated ACI's capabilities, with the adoption of digital pathology systems and advanced imaging technologies streamlining diagnostics and improving overall service quality. These enhancements align with broader **Healthcare Management** and **Oncology** best practices, positioning ACI as a leader in efficient hospital operations across Asia.[1]

A pivotal element of ACI's innovation is its leadership in research and adoption of cutting-edge technology. Serving as the principal investigator in seven global clinical trials, ACI has pushed the boundaries of cancer treatment research. Notably, it launched the Philippines' first **CyberKnife S7 (CKS7)**, an AI-enabled radiosurgery system that represents a quantum leap in precision oncology. This non-invasive, frameless system offers real-time tumor tracking and sub-millimeter accuracy, delivering high-dose radiation in just one to five sessions for tumors throughout the body. As of 2025, ACI houses one of only three operational CKS7 units in Asia, solidifying its status as a national and regional referral center for complex cases.[1]

The CKS7's efficiency addresses critical shortages in radiation therapy resources across the Philippines and neighboring countries, minimizing patient travel burdens, logistical challenges, and treatment disruptions. By attracting patients nationally and internationally, it not only enhances revenue streams but also reinforces ACI's role in **Surgical Equipment** and **Oncology** advancements. Hospital leadership emphasized that these strategies have transformed operational challenges into opportunities, yielding transformative patient outcomes driven by collaboration and compassion.[1]

The awards from the Asian Management Excellence Awards, presented by Asian Business Review Magazine, underscore ACI's excellence in employee engagement, diversity, inclusion, and health initiatives. This recognition highlights how integrated **Facilities Management**, technological deployment, and team synergy can drive sustainable growth in hospital settings. For healthcare administrators and clinical leaders in Asia, ACI's model offers actionable insights into balancing efficiency with innovation amid rising demands.[1]

Looking ahead, such achievements signal a maturing landscape for **Healthcare Information Technology** integration and **Patient Monitoring** in oncology, where AI-driven tools like CKS7 exemplify digital transformation. Procurement professionals may note the strategic value of investing in such systems to enhance competitive positioning and patient throughput. This development is particularly relevant for decision-makers focused on **Regulatory** compliance through PhilHealth expansions and equitable care models.[1]

In summary, Asian Hospital's dual awards reflect a blueprint for excellence in Asian hospital management, emphasizing interdisciplinary care, technological adoption, and resilient operations. Continued emphasis on these pillars will likely influence regional standards in cancer care delivery.[1]

The Philippines' Asian Hospital and Medical Centre has achieved remarkable recognition at the Asian Management Excellence Awards 2026, securing two distinguished titles: Philippines Innovator of the Year - Healthcare and Philippines Team of the Year - Healthcare. These awards celebrate the outstanding performance of its Asian Cancer Institute (ACI), which exceeded organisational targets through enhanced operational efficiency, superior patient experience, and pioneering clinical innovations, particularly the introduction of the CyberKnife S7 system.[1]

In the fiscal period of 2024-2025, ACI generated PHP363.8 million in revenue, surpassing its ambitious 30.2% growth target by achieving 41% year-to-date growth as of September 2025. This success stems from a meticulously coordinated, team-based approach that integrates six specialised, interdisciplinary centres: Breast, Simply Women, Emmanuel, Chrys 1 Infusion, Conquer C, and Chrys 2 Supportive and Integrative Care. These centres form a seamless continuum of care, addressing every phase of the cancer journey from prevention and diagnosis through treatment, survivorship, and end-of-life support.[1]

Facing significant operational challenges, the ACI team implemented strategic solutions including active patient navigation, extended operating hours, expansion of the infusion unit with reduced turnaround times, seamless interdisciplinary integration of CyberKnife technology, bolstered manpower resources, and comprehensive supportive care services. These measures not only optimised workflows but also elevated service quality across the board.[1]

ACI has also prioritised equitable access to care by expanding PhilHealth-aligned packages, providing chemotherapy brand options, and enhancing access to innovative drug assistance programmes. Infrastructure upgrades, such as digital pathology systems and advanced imaging technologies, have further strengthened diagnostic and treatment capabilities, ensuring high standards of precision and reliability in patient management.[1]

A key highlight is ACI's leadership in research and technology adoption. Serving as principal investigator in seven global clinical trials, the institute has positioned itself at the forefront of oncology advancements. The launch of the Philippines' first CyberKnife S7 (CKS7), an AI-enabled radiosurgery system, marks a transformative milestone. This non-invasive, frameless technology offers real-time tumour tracking and sub-millimetre precision, delivering high-dose radiation in just one to five sessions for tumours throughout the body. As of 2025, ACI operates one of only three such units in Asia, solidifying its status as a national and regional referral centre for complex cases.[1]

The CKS7 system's efficiency addresses critical shortages in radiation therapy resources across the Philippines, minimising patient travel burdens, logistical challenges, and treatment disruptions. By attracting patients from across the country and neighbouring nations, ACI enhances its role in regional healthcare delivery. The awards statement from Asian Hospital emphasised: "These collective strategies enabled the ACI Team to transform challenges into opportunities for improvement, resulting in exceptional care for patients and families. The ACI Team’s unwavering commitment to stewardship proves that when collaboration and compassion drive healthcare, transformative outcomes are achieved."[1]

This dual recognition underscores ACI's excellence in operational triumphs over the past year and the groundbreaking impact of CKS7 in redefining cancer care standards in the Philippines. The Asian Management Excellence Awards, presented by Asian Business Review Magazine, honours top business leaders, innovators, and companies across Asia for achievements in employee engagement, diversity, inclusion, and health initiatives. For hospital administrators and clinical leaders, this case exemplifies how integrated care models, technological investments, and team coordination can drive revenue growth, improve patient outcomes, and navigate operational pressures effectively.[1]

Looking ahead, such innovations signal a broader trend in Asian healthcare towards precision oncology and multidisciplinary approaches, offering actionable insights for facilities management and strategic partnerships in the region. ACI's model of combining clinical trials, advanced robotics, and patient-centric services sets a benchmark for oncology departments aiming to enhance competitiveness and service equity.[1]

In summary, these awards validate Asian Hospital's strategic focus on innovation and teamwork, providing a blueprint for other healthcare organisations pursuing sustainable growth in cancer care delivery.